s6y

Bionano Genomics, Inc.

Nasdaq
BNGO
CIK
1411690
Industry
Laboratory Analytical Instruments
Based in
San Diego, California
Incorporated in
Delaware
Fiscal year ends
December 31
SEC filer category
Non-accelerated filer, Smaller reporting company
Employer ID (EIN)
26-1756290
Formerly
BioNano Genomics, Inc, BioNanomatrix Inc

Key figures

Fiscal year to Dec 2025 Dec 2024 Dec 2023 Dec 2022 Dec 2021
Revenue $28.5M$30.8M$36.1M$27.8M$18.0M
Operating income −$33.3M−$104.0M−$215.2M−$131.7M−$77.1M
Net income −$26.4M−$112.0M−$232.5M−$132.6M−$72.4M
Diluted EPS −$4.85−$88.13−$408.60−$4.58−$0.26
Cash from operations −$16.3M−$68.9M−$125.2M−$124.8M−$71.9M
Total assets $73.6M$76.7M$214.4M$307.5M$377.1M
Shareholders’ equity $44.4M$35.4M$96.2M$249.4M$337.1M

From the company’s annual reports to the SEC. Each year links to its report.

Financials 33

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K Annual Report for period ending Dec 31, 2024
  9. 10-Q Quarterly Report for period ending Sep 30, 2024
  10. 10-Q Quarterly Report for period ending Jun 30, 2024

All 33 financials filings

News 124

  1. 8-K Financial results
  2. 8-K Regulation FD disclosure
  3. 8-K Financial results
  4. 8-K Other events
  5. 8-K Director or officer change
  6. 8-K Other events
  7. 8-K Shareholder vote results
  8. 8-K Financial results
  9. 8-K Director or officer change; Other events
  10. 8-K Financial results

All 124 news filings

Ownership 266

  1. SCHEDULE 13G/A Major shareholder report (passive investor)
  2. SCHEDULE 13G Major shareholder report (passive investor)
  3. 4 Luderer Albert: Change in insider ownership
  4. 4 Change in insider ownership
  5. SCHEDULE 13G/A Major shareholder report (passive investor)
  6. 4 Change in insider ownership
  7. 3 Initial statement of insider ownership
  8. 4 Change in insider ownership
  9. 3 Initial statement of insider ownership
  10. 4 Dixon Jonathan V.: Change in insider ownership

All 266 ownership filings

Prospectus 78

  1. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  2. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  3. S-3/A Registration statement for specified transactions by certain issuers
  4. S-1 General form of registration statement for all companies including face-amount certificate companies
  5. S-3 Registration statement for specified transactions by certain issuers
  6. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  7. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  8. 424B4 Prospectus filed pursuant to Rule 424(b)(4)
  9. S-1 General form of registration statement for all companies including face-amount certificate companies
  10. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

All 78 prospectus filings

Proxies 40

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements
  3. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  4. DEF 14A Definitive proxy statements
  5. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  6. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  7. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  8. DEF 14A Definitive proxy statements
  9. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  10. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

All 40 proxies filings

Other 93

  1. EFFECT Notice of Effectiveness
  2. EFFECT Notice of Effectiveness
  3. ARS Annual report to security holders
  4. EFFECT Notice of Effectiveness
  5. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  6. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  7. UPLOAD Letter (PDF)
  8. ARS Annual report to security holders
  9. EFFECT Notice of Effectiveness
  10. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

All 93 other filings

Others in Laboratory Analytical Instruments

Every company in this industry